Child and Adolescent Mental Health
Volume 20,Issue 1,pages 20–25,February 2015
DOI:10.1111/camh.12033
Change in metabolic parameters and weight in response to risperidone monotherapy in young children with nonpsychotic disorders: a prospective open-label study
Burcu Ersoz AlanS. Ebru Cengel Kultur
Abstract
Background
This study investigates changes in metabolic parameters in prepubertal children after 14–16 weeks of treatment with low-dose risperidone.
Method
Thirty-one children (mean age 5.46&plun;1.98years) were treated with risperidone (0.25–1mg/day; 0.01–0.07mg/kg/day). Patients were excluded if they were using any medication other than risperidone or were diagnosed with any medical problem in addition to a non-psychotic disorder.
Results
Weight (Δ: 2.51&plun;1.94kg), height (Δ: 0.03&plun;0.04cm), BMI (Δ: 0.82&plun;1.4), BMI percentile (Δ: 9.72&plun;16.40), BMI z-score (Δ: 0.33&plun;1.03), triglyceride (Δ: 1.50&plun;23.97mg/dl), very low density lipoprotein (Δ: 2.99&plun;4.76mg/dl), insulin (Δ: 3.07&plun;3.38mIU/ml), and leptin (Δ: 3.02&plun;4.69ng/ml) were significantly increased (p<.05).
Conclusion
The metabolic side effects of risperidone must be carefully monitored in prepubertal children.
